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Summary Using a panel of ten polymorphic markers, we examined the frequency of loss of heterozygosity
(LOH) on chromosome 17 in 55 sporadic ovarian tumours. LOH on 17p and 17q was observed to be 50% and
62% respectively. LOH at D17S5 was detected in 24/36 (67%) ofmalignant cases and in 19/43 (44%) at TP53;
the marker D17S855 intragenic to the BRCAJ gene showed allele loss in 50% (20/40) cases. The data presented
here suggest that loss of the whole chromosome 17 is a relatively frequent event (30%) in ovarian carcinomas
and this observation is especially frequent for serous, transitional cell and anaplastic histological subtypes.
Mucinous and endometrioid ovarian tumours showed only short interstitial deletions (4/11, 36%). The overall
frequency of the short deletions was relatively low (7/43, 16%) in our panel of carcinomas. Amplification of
c-erbB-2/neu oncogene was detected in 32% (11/34) of the carcinomas tested; the gene was amplified only in
those histological subtypes in which high incidence of LOH on chromosome 17 was observed, and was
associated with advanced stages of the disease. We conclude that different histological types of tumour may
have different aetiological mechanisms, and tumour-suppressor genes on chromosome 17 might be associated
specifically with serous and transitional cell ovarian carcinomas.
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Molelcular genetic analysis of ovarian carcinomas has
revealed a significant role for chromosome 17 in pathogen-
esis of ovarian malignancies. These studies have shown that
loss of heterozygosity (LOH) for regions of chromosome 17
is a frequent event, probably indicating the inactivation of
suppressor genes present on this chromosome (Eccles et al.,
1990; Lee et al., 1990; Russell et al., 1990; Foulkes et al.,
1991; Phillips et al., 1993). The search for loss of
constitutional heterozygosity with polymorphic genetic
markers is now a widely accepted approach to indicate
areas on the genome where inactivation of tumour-suppressor
genes may occur.
The p53 tumour-suppressor gene is the most commonly
mutated gene in human cancer (Greenblatt et al., 1994), and
LOH on 17p at or close to the p53 locus is present very
frequently in ovarian carcinomas (Okamoto et al., 1991; Tsao
et al., 1991; Eccles et al., 1992a; Cliby et al., 1993; Foulkes et
al., 1993; Yang-Feng et al., 1993).
The breast and ovarian cancer susceptibility locus,
BRCA1, has been cloned from the chromosomal region
17q21 (Miki et al., 1994). The first mutations of the BRCAI
gene observed in sporadic ovarian carcinomas have recently
been reported (Merajver et al., 1995). Frequent losses in this
region (at 17ql2-23) and at a more distally located locus (at
17q22-23) have been observed (Hall et al., 1990; 1992;
Narod et al., 1991; Jacobs et al., 1993; Saito et al., 1993;
Cornelis et al., 1995).
In addition to the studies addressing the importance of
specific tumour-suppressor genes, several groups examined
the frequency of oncogenes activated in ovarian carcinomas.
Amplification of the c-erbB-2/neu oncogene was observed
most frequently, and was associated with advanced stages
and poor clinical outcome (Slamon et al., 1989). In order to
contribute to the clarification of the biological significance of
genetic alterations on chromosome 17 in ovarian cancer, in
this study we further examined the amplification of c-erbB-2
oncogene and the frequencies of losses of heterozygosity at
ten different loci on chromosome 17 in 50 epithelial and in
five non-epithelial ovarian tumours.
Materials and methods
Samples
Fresh tumour tissue samples were collected from consenting
patients undergoing surgery for ovarian cancer, who had
received no prior therapy. Samples were collected in dry ice
and stored at - 80°C until processed. Histopathological
classification of the ovarian tumours was carried out
according to the WHO classification. The distribution of
the epithelial tumours was as follows: 24 serous, six
mucinous, seven endometrioid, one clear cell, six transitional
cell, three anaplastic and three mixed cell tumours. Stages of
the disease were assigned according to the classification
scheme accepted by the general assembly of the International
Federation of Gynecologists and Obstetricians (FIGO).
DNA extraction, Southern analysis
DNA was extracted by standard methods from fresh-frozen
samples and from peripheral lymphocytes from all patients.
Southern analysis was performed by standard techniques. For
typing marker D17S4, RsaI-digested genomic DNA was
hybridised with the whole linearised plasmid (pTHH59). For
detection of c-erbB-2 oncogene amplification, PstI-digested
ovarian carcinoma DNA was hybridised with labelled human
c-erbB-2 probe, washed, autoradiographed, and reprobed
with glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
probe, specific for a single-copy gene.
Microsatellite markers
Eight of the ten polymorphic markers (TP53, D17S261,
D17S250, THRAI, D17S855, D17S579, D17S588 and
NME1) detected (CA)n dinucleotide repeat polymorphisms,
and two of them were VNTR markers (Dl7S5 and D17S4).
The samples were scored for LOH by comparing the
autoradiographic signals of the corresponding blood and
tumour tissue samples.
PCR amplifications
PCR reactions were carried out in 40,l reaction volumes
typically containing 50-100 ng genomic DNA, 10 pmol each
primer, 1.5 mM magnesium chloride, 200 giM each dNTP,
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AmpliTaq DNA Polymerase (Perkin Elmer Cetus). The 5'
primers of microsatellite markers were end labelled with
[y-32P]ATP using T4 polynucleotide kinase B. The samples
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were amplified in 28-35 cycles, each containing a denatura-
tion step (1 min at 95°C), an annealing step (1 or 2 min at
the appropriate annealing temperature) and an extension step
(1 min at 72°C). For typing the TP53 marker we used a two-
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Figure 1 LOH pattern of chromosome 17 in ovarian tumours. The physical location and order of loci are shown below the
chromosome. Clinical stage, histological grade and status of c-erbB-2 amplification are also indicated. Black, white and hatched
ovals represent loss of heterozygosity, non-informative patients and cases with both alleles retained respectively.
I I
I
I
11
I
I
I
I
I
11
11
11
I
11Allele loss from chromosome 17 in ovarian cancer
aP J Papp et al
1594
step PCR amplification protocol decribed by Jones and
Nakamura (1992). In all cases, PCR cycles were preceded by
an initial denaturation step (10 min at 95°C) and followed by
an elongation step (7 min at 72°C). PCR products of
microsatellite markers were run on a standard sequencing
gel using an M13 sequencing reaction as size marker. After
fixation and drying, gels were autoradiographed for 1 -3 days
at room temperature. Amplified fragments of the YNZ22
marker with VNTR polymorphism were run on 2% agarose
(SeaKem) gel and visualised by ethidium bromide staining.
Statistical analysis
All comparisons between groups and/or parameters were
performed using Fisher's exact t-test. One-tailed P-
values<0.05 were considered statistically significant.
Results
After characterising all 55 cases of primary tumours of the
ovary by histology and grade, DNA extracted from tumours
and corresponding normal DNAs were screened for allele loss
of both arms of chromosome 17 using ten polymorphic
markers. The informativity of the markers and the
frequencies of LOHs are summarised in Table I. The pattern
of losses is presented in Figure 1. In non-epithelial ovarian
tumours allelic deletion was relatively common; three out of
five non-epithelial malignant tumours showed deletions
affecting only one marker (TP53) in one case and long
chromosomal fragments in the two other cases.
Table I Informativity of the markers and frequencies of LOH in
ovarian tumours
Probe HGMa locus Informative/total LOH/informative
name name cases (%) cases (%)b
YNZ22 D17S5 38/45 (84) 23/32 (72)
TP53CA TP53 48/54 (89) 18/39 (50)
mfd4l D17S261 28/48 (58) 12/22 (55)
mfdl5 D17S250 41/54 (76) 17/32 (53)
THRAI THRAI 44/51 (86) 16/35 (46)
AFM238yg9 D17S855 45/53 (85) 18/35 (51)
mfdl88 D17S579 44/54 (81) 20/36 (56)
42D6 D17S588 44/53 (83) 17/34 (50)
nm23 NME1 37/49 (76) 19/30 (63)
THH59 D17S4 24/46 (52) 11/19 (58)
aHuman Genome Mapping. bLOH data are formalignant epithelial
tumours.
From our small panel of informative benign and border-
line epithelial tumours, only the tumour with borderline
malignancy showed LOH, while no allele loss was seen in any
of the benign tumours.
Out of 44 carcinoma samples, 75% presented allele loss
from chromosome 17. These results indicate strongly
significant correlation (P=0.002) between malignancy and
LOH.
Allelic deletion of p53 was observed in 50% (18/39) of
malignant epithelial tumours. The frequent occurrence (23/32,
72%) of LOH at D17S5 may imply the presence of a tumour-
suppressor gene at the region telomeric to p53. The allele
losses involved the BRCAJ gene defined by the intragenic
marker D17S855 in 51% (22/43) of the malignant cases
tested.
Table II shows loss of heterozygosity according to the
histopathological subtypes. There was a statistically signifi-
cant difference (P=0.006) in frequencies of chromosome 17
LOH between serous and transitional cell vs mucinous and
endometrioid histological groups of malignant ovarian
tumours. The overwhelming majority of losses was seen in
the subtypes of serous (16/20, 80%), transitional cell (6/6,
100%), anaplastic (3/3, 100%) and mixed cell (3/3, 100%)
ovarian carcinomas. In these subtypes not only the incidence
of LOH was higher, but also longer chromosomal regions
were involved. At least 19 cases out of 43 carcinomas (44%)
were suggestive of the loss of the whole long arm, whereas
37% (16/43) showed loss of the short arm. (As an example,
pattern of allelic losses of patient no. 57 is shown in Figure
2). Loss of the entire chromosome 17 was found in 30% (13/
44) of carcinomas examined. In contrast, only one of four
mucinous and three of six endometrioid tumours presented
allelic deletions, affecting only one or two markers in each
case. The overall frequency of short, interstitial deletions was
relatively low (7/43, 16%) in our panel ofmalignant tumours.
To elucidate the genetic imbalance of ovarian carcinoma
cells further, amplification of the c-erbB-2 oncogene, which is
associated with poor prognosis in ovarian as well as in breast
carcinomas, was also evaluated (Figures 1 and 3). The
frequency of amplification of this gene in our ovarian
tumours was determined and related to the clinical stage
and histological grade of the disease. We found 2-5-fold
amplification of the c-erbB-2 oncogene in 11 of 34 (32%) of
the carcinomas and neither benign tumours nor non-epithelial
malignant cases showed c-erbB-2 amplification (Table II). All
tumours, except one containing amplified c-erbB-2, were of
advanced stage, and amplification of c-erbB-2 was associated
(P=0.011) with higher grade. c-erbB-2 was found to be
amplified only in those histological subtypes, in which high
incidence of LOH on chromosome 17 was observed.
Table II Loss of heterozygosity and c-erbB-2 amplification by histopathological subtypes of ovarian tumours
Histopathological Loss ofheteroxygosity/informative cases (%) Amplification
type of tumours 17p LOH 17q LOH Total LOHa of c-erbB-2 (%)
Epithelial ovarian tumours
Benign 0/5 (0) 0/5 (0) 0/5 (0) 0/5 (0)
Borderline 0/1 (0) 1/1 (100) 1/1 (100) 0/1 (0)
Malignant
Serous 14/20 (70) 16/20 (80) 16/20 (80) 5/21 (24)
Mucinous 0/4 (0) 1/4 (25) 1/4 (25) 0/2 (0)
Endometrioid 1/7 (14) 2/7 (29) 3/7 (43) 0/2 (0)
Clear cell 0/1 (0) 1/1 (100) 1/1 (100) 0/1 (0)
Transition cell 5/5 (100) 5/6 (83) 6/6 (100) 2/4 (50)
Anaplastic 3/3 (100) 3/3 (100) 3/3 (100) 2/3 (67)
Mixed 2/3 (67) 3/3 (100) 3/3 (100) 2/3 (67)
Non-epithelial ovarian
tumours
Sex cord tumours 2/4 (50) 1/4 (25) 1/4 (25) 0/3 (0)
Germ cell tumours 0/1 (0) 1/1 (100) 1/1 (100) 0/1 (0)
All cases 27/54 (50) 34/55 (62) 37/55 (67) 11/44 (25)
aLOH affecting at least one marker on chromosome 17.Allele loss from chromosome 17 in ovarian cancer
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Figure 2 Results of LOH analyses of patient no. 57 (see also in Figure 1). 'N' and 'T' indicate matched DNA samples isolated
from peripheral blood leucocytes and tumour tissue respectively. Human Genome Mapping locus names are given on the upper
abscissa. Marker D17S261 is not informative; both alleles of markers TP53, D17S250 and THRAI are retained; all other markers
show loss of heterozygosity.
Patient no. Co 52 53 60 88 reports of Foulkes et al. (1993) and Tavassoli et al. (1993),
who noted trequent loss ot the whole chromosome 17 in
ovarian carcinomas. The observation that LOH affects one
whole copy of the chromosome 17 suggests the possible
involvement of multiple chromosome 17 loci in the
pathogenesis in some ovarian tumours. This is consistent
with the presence of tumour-suppressor genes on both arms
of this chromosome, including p53, BRCAJ and a potential
tumour-suppressor gene distal to BRCAI (Jacobs et al., 1993;
Godwin et al., 1994).
Specifically, all losses of the whole chromosome 17 and the
vast majority of losses of large chromosomal regions were
detected in serous, anaplastic, transitional cell or mixed cell
ovarian carcinomas. It is noteworthy that serous carcinoma
samples without any loss (cases 53, 58, 90 and 92) are all of
grade I. Interstitial deletions of chromosome 17 affected the
long arm of the chromosome in all cases. The frequency of
- nW i.i (w O inese snort aeietions was reiativeiy iOW kio-/o) in our panei OI
Figure 3 Example for detection of c-erbB-2 amplification using malignant epithelial tumours, occurring in mucinous,
Southern analysis after PstI digestion of the DNA. Patients no. endometrioid and clear cell histological subtypes.
52 and 60 demonstrate more than 2-fold amplification. The same LOH on the short arm of the chromosome, including the
filter was reprobed with the GAPDH probe (lower panel); Co, p53 locus, was observed in ovarian carcinomas by several
normal lymphocyte control. groups (Coles et al., 1990; Eccles et al., 1992b; Kohler et al.,
1993). In our studies there was 50% LOH at p53. Allelic
losses and mutations of the p53 gene are common genetic
Discussion events in ovarian cancer (Okamoto et al., 1991; Millner et al.,
1993), indicating a direct involvement of p53 in ovarian
Very frequent LOH occurred at all chromosome 17 loci malignancies. On the basis of LOH studies, several reports
examined in this study. In contrast to reports on chromosome have suggested that in addition to p53 there may be a gene
17 in breast cancer (Lindblom et al., 1993) and other telomeric of p53 (at 17pl3.3), which is acting as a tumour
chromosomes involved in ovarian carcinogenesis (e.g. suppressor or a regulator of p53 expression in breast an-d
chromosome 6) (Wan et al., 1994), in which LOH affects ovarian carcinogenesis (Tsao et al., 1991; Wales et al., 1995;
only specific regions, in a fairly high proportion of our Stack et al., 1995). Coles et al. (1990) reported a significantly
carcinomas the loss appeared to involve the whole higher frequency of LOH at 17pl3.3 than at the p53 locus.
chromosome (30%). These results are in line with the Although D17S5 and p53 deletions were observed together in
c-erbB-2
GAPDHAllele loss from chromosome 17 in ovarian cancer
J Papp et al
1596
56% of the cases in our studies, eight tumours showed both
loss of D17S5 and retention of p53, which may indicate a
second putative tumour-suppressor gene locus in this region.
(A typical case is shown in Figure 2.)
Allelic losses on 17p have been observed in various
malignancies, but LOH on 17q appears to be more specific
for breast and ovarian carcinomas. The familial breast/
ovarian cancer locus (BRCA1) is mapped to 17q21, and the
BRCAI gene has already been isolated (Miki et al., 1994). In
a multicentre study, we recently reported LOH in 86% of
familial breast and ovarian tumours, which invariably
involved the wild-type allele (Cornelis et al., 1995). These
results strongly support the case that BRCAJ is a tumour-
suppressor gene and the loss of heterozygosity is greatly
favoured to inactivate it fully. Somatic point mutations in
BRCAJ are relatively infrequent in sporadic breast and
ovarian cancer, but deletion of one BRCAJ allele occurs in
approximately 50% of sporadic breast and 70% of sporadic
ovarian cancer (Futreal et al., 1994; Merajver et al., 1995;
Holt et al., 1996). The long arm of chromosome 17 displayed
LOH in 50% of our malignant cases in the BRCAI gene, and
63% of the cases with the marker close to the NMEl
metastasis-suppressor gene. Most of the cases of LOH on 17q
included the region in which the BRCAJ gene is located.
However, three cases with telomeric losses showed no
deletion in this region. In our samples, the frequency of
allele loss was always higher when telomeric markers were
used. However, the LOH detected with markers close to the
telomeric regions (like D17S5 and D17S4) may be indicative
of chromosome 17 telomeric losses without any association
with specific genes. Telomeric deletion on 17q, which has
been shown to be associated with chromosomal instabilities
in a number of human tumours, including ovarian cancer
(Hastie et al., 1990), can also contribute to loss of large
chromosome fragments.
Saito et al. (1992, 1993) found a significant difference in
the frequency of LOH at 6q and 17q21.3 among three
different histopathological groups: tumours of the serous type
showed LOH more often than did mucinous or clear cell
types. Our results reported here demonstrate that losses
affecting the whole chromosome 17 or long fragments of
either arm are characteristic only for serous, transitional cell
and anaplastic groups, while mucinous, endometrioid and
clear cell carcinomas either show no LOH or only interstitial
allelic losses. Most recent support for preferential involve-
ment of serous ovarian carcinomas in chromosome 17 loss
came from Pieretti et al. (1995).
In our studies the c-erbB-2/neu locus was found to be
amplified in 32% of the malignant cases and c-erbB-2
amplification was more characteristic of higher histological
grade and clinical stage. These results are in agreement with
the report of Slamon et al. (1989), who first demonstrated a
relationship between c-erbB-2 amplification and poor
prognosis for ovarian as well as breast carcinomas. The
c-erbB-2 gene was amplified only in those histological
subtypes (serous, anaplastic, transitional cell and mixed cell)
in which high incidence of LOH occurred. In 10 out of 11
cases, both amplification and loss of the same region
(D17S250, THRAI) were observed. The term allelic
imbalance, introduced by Devilee and Cornelisse (1994),
would provide a better description of such DNA changes as
it permits interpretation of imbalance of allelic signals,
irrespective of whether it is an allelic loss or gain.
The data presented here further suggest that allelic
imbalance of chromosome 17 is an important genetic event
in epithelial ovarian carcinogenesis. Our results also indicate
that there might be different genetic pathways in the
aetiology of histological subtypes of ovarian cancer.
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